Resistell’s first patients recruited for international clinical study
HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of Carevix™ from the U.S. Food and Drug Administration (FDA). ASPIVIX’s novel Cervical Stabilizer will allow millions of women across the USA access to significantly less painful treatments and IUD insertions.
New Year’s resolutions can be a powerful way to make positive changes in life and achieve goals.
Increasing patients’ safety and care in research is vital when preparing and conducting your study. From a HEMEX perspective, we are tackling in this article four important points you should consider during the process.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
Big congratulations to Sedimentum, who has launched a contactless emergency product for Swiss
households: “SAFE-living”, the intelligent fall detection service. An innovative solution that
doesn’t require wearing a bracelet or pressing an emergency button.
From market research to funding, today, we will dismantle the top 5 reasons for startup failure. At HEMEX, we have seen many cases in our years of experience in this field. For this reason, we hope to give you some hints to look out for while navigating the ever-changing startup ecosystem.
Callum is a student at Gymnasium Liestal. He applied for a one-week internship at HEMEX and has spent the last week accompanying the team during our daily activities. Here’s a sum-up of his week written by Callum himself.
This milestone shows the devotion of our QA team to ensuring HEMEX’s high standards and commitment to quality. Achieving this certification was one of the milestones we wished to accomplish in 2022.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
- 1
- 2